Study finds arthritis drugs tocilizumab and sarilumab help reduce deaths from COVID-19-Health News, Firstpost

Arthritis drugs tocilizumab and sarilumab reduce risk of death and need for ventilators in hospital patients COVID-19[female[feminine patients, according to an analysis of nearly 11,000 patients released Tuesday.

The study appeared in the Journal of the American Medical Association and prompted the World Health Organization (WHO) to recommend the use of drugs, called IL-6 inhibitors, in addition to corticosteroids in patients. with severe or critical Covid.

Manu Shankar-Hari, professor at King’s College London and lead author of the article, told AFP the research represented “definitive evidence” in favor of the drugs after previous studies produced mixed results.

Among hospitalized Covid patients, administering any of the drugs in addition to corticosteroids reduced the risk of death by 17%, compared to using corticosteroids alone.

In patients who were not on a ventilator, the risk of switching to mechanical ventilation or dying was reduced by 21%, compared to using corticosteroids alone.

Critically ill Covid patients experience an overreaction of the immune system known as a “cytokine storm” which can cause severe organ damage and death.

Tocilizumab and sarilumab are used to treat rheumatoid arthritis, an autoimmune disease, by inhibiting the effects of interleukin (IL) -6, a type of protein called a cytokine that signals the body to trigger an inflammatory response.

But previous research to find out if IL-6 inhibitors can be helpful against severe Covid has reported various benefits, no effects, and harms.

This prompted the WHO to coordinate the new study which combined data from 27 randomized trials conducted in 28 countries.

The analysis included information on 10,930 patients, of which 6,449 were randomized to receive interleukin-6 inhibitors and 4,481 to usual care or placebo.

Overall, the risk of dying within 28 days was 22 percent compared to a presumed risk of 25 percent in people receiving only usual care.

Outcomes were best when patients also received corticosteroids, with a 21 percent risk of death versus 25 percent for those receiving usual care.

This means that for every 100 of these patients, four more will survive.

The study also looked at the impact of these drugs on patients’ progression to ventilators or death.

Among patients who also received corticosteroids, the risk was found to be 26% for those receiving IL-6 inhibitors, compared with 33% assumed for those receiving usual care.

In other words, for 100 of those patients, another seven will survive and avoid mechanical ventilation.

Tocilizumab and sarilumab, which are given by infusion or injection, are currently recommended for use with corticosteroids in severe Covid patients by Great Britain. The United States also recommends tocilizumab with corticosteroids.

Shankar-Hari said he hopes global organizations such as the WHO can now push to improve access to medicines for low- and middle-income medicines where the current cost might be prohibitive for widespread use.